Brandon Bortner is a partner in the Securities and Capital Markets practice, based in the firm's Washington, D.C. office. Brandon practices corporate and securities law, with an emphasis on capital markets transactions, public and private financings, and public company representation. On capital markets matters, Brandon regularly advises issuers, investors, sponsors, and investment banks in public and private equity-based financings, debt and hybrid corporate finance transactions, including convertible securities, restructurings, and other financing transactions.
A significant portion of his practice involves general corporate work for ongoing clients on matters such as SEC reporting compliance, securities and disclosure issues, and corporate governance matters. Brandon also has extensive experience with alternative financings, including Private Investments in Public Equity (PIPEs), tax-advantaged IPO structures, Real Estate Investment Trusts (REITs), at-the-market (ATM) programs, convertible and non-convertible preferred stock, and investment grade and high-yield debt securities.
Georgetown University Law Center, JD, 2004
Washington & Lee University, BA, 2000
Mr. Bortner's recent client successes include representing:
2U, Inc. in its $330 million Rule 144A convertible senior notes offering and capped call, as well as its underwritten $310 million follow-on equity offering
2U, Inc. in its $750 million acquisition of Trilogy Education and related $200 million direct lender term loan financing
Teladoc Health in its Rule 144A offerings of: (i) $1.0 billion 1.25% convertible senior notes and (ii) $287.5 million 1.375% convertible senior notes, as well as its $400 million follow-on offering
Emerald Holding in its $400 convertible preferred stock PIPE
General Motors Financial Company, Inc. in its underwritten offerings of: (i) $500 million fixed rate reset Series C preferred stock offering; (ii) $2.5 billion multi-tranche senior notes; (iii) $2.0 billion multi-tranche senior notes; (iv) $1.5 billion 5.200% Senior Notes due 2023; (v) $1.25 billion 2.900% Senior Notes due 2025; (vi) $1.25 billion 3.550% Senior Notes due 2022; (vii) $2.5 billion $2.0 billion multi-tranche senior notes; (viii) $1.35 billion multi-tranche senior notes; and (ix) $500 million fixed-to-floating Series B preferred stock offering
DXC Technology Company in its underwritten offerings of: (i) $1.0 billion multi-tranche senior notes; (ii) €650,000,000 1.750% Senior Notes due 2026; and (iii) £250,000,000 2.750% Senior Notes due 2025
DXC Technology Company in its offer to exchange all outstanding Enterprise Services LLC 7.45% Senior Notes due 2029 and related consent solicitation
CoreSite Reality Corp. in multiple 4(a)(2) senior notes offerings
CoreSite Reality Corp. and The Carlyle Group in multiple underwritten secondary block trades
Lindblad Expeditions Holdings, Inc. in its $85 million convertible preferred stock PIPE
Underwriters in a global energy company's offerings of: (i) €4.5 billion multi-tranche senior notes; (ii) $10.75 billion multi-tranche senior notes; and (iii) $8.5 billion multi-tranche senior notes
Multiple venture round financings for FiscalNote Holdings, Inc.
The Carlyle Group in its $435 million convertible preferred stock PIPE in WildHorse Resource Development Corporation
AIT Therapeutics, Inc. in its common stock PIPE offering
Selecta Biosciences, Inc. in its common stock PIPE offering
Pint Pharma International S.A. in its PIPE and collaboration agreement with Onconova
Adimab, LLC in its holding company restructuring and related financing
Clearside Biomedical, Inc., CommScope Holding Company, Inc. and Selecta Biosciences, Inc. in their initial public offerings
Underwriters in initial public offerings by Ra Pharmaceuticals, Inc., Intellia Therapeutics, Inc., and Eloqua, Inc.